These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 35055006)

  • 1. Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives.
    Ciardiello D; Maiorano BA; Parente P; Rodriquenz MG; Latiano TP; Chiarazzo C; Pazienza V; Guerrera LP; Amoruso B; Normanno N; Martini G; Ciardiello F; Martinelli E; Maiello E
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer.
    Yue S; Zhang Y; Zhang W
    Curr Treat Options Oncol; 2024 Aug; 25(8):1089-1111. PubMed ID: 39066855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances of immunotherapy for biliary tract cancer.
    Rizzo A; Ricci AD; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):527-536. PubMed ID: 33215952
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunotherapeutic Approaches to Biliary Cancer.
    Shah UA; Nandikolla AG; Rajdev L
    Curr Treat Options Oncol; 2017 Jul; 18(7):44. PubMed ID: 28660602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab: an investigational agent for the treatment of biliary tract cancer.
    Di Federico A; Rizzo A; Ricci AD; Frega G; Palloni A; Tavolari S; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):325-332. PubMed ID: 33307866
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future.
    Blair AB; Murphy A
    Curr Probl Cancer; 2018; 42(1):49-58. PubMed ID: 29501212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapies in clinical development for biliary tract cancer.
    Vogel A; Bathon M; Saborowski A
    Expert Opin Investig Drugs; 2021 Apr; 30(4):351-363. PubMed ID: 33382361
    [No Abstract]   [Full Text] [Related]  

  • 8. Continuum of care for advanced biliary tract cancers.
    Vienot A; Neuzillet C
    Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):810-824. PubMed ID: 32586782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets.
    Tariq NU; Vogel A; McNamara MG; Valle JW
    Oncol Res Treat; 2018; 41(5):298-304. PubMed ID: 29705791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.
    Conci S; Catalano G; Roman D; Zecchetto C; Lucin E; De Bellis M; Tripepi M; Guglielmi A; Milella M; Ruzzenente A
    Int J Med Sci; 2023; 20(7):858-869. PubMed ID: 37324191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
    Athauda A; Fong C; Lau DK; Javle M; Abou-Alfa GK; Morizane C; Steward K; Chau I
    Cancer Treat Rev; 2020 Jun; 86():101998. PubMed ID: 32203843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers.
    Zhang R; Puzzoni M; Mariani S; Zheng Y; Liscia N; Guo Y; Donisi C; Liu Y; Impera V; Fang W; Scartozzi M
    Cancer Sci; 2021 Dec; 112(12):4819-4833. PubMed ID: 34534382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.
    Sicklick JK; Fanta PT; Shimabukuro K; Kurzrock R
    Cancer Metastasis Rev; 2016 Jun; 35(2):263-75. PubMed ID: 26857926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer.
    Rizzo A; Ricci AD; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):343-350. PubMed ID: 33645367
    [No Abstract]   [Full Text] [Related]  

  • 15. Systemic treatment options for advanced biliary tract carcinoma.
    Xie C; McGrath NA; Monge Bonilla C; Fu J
    J Gastroenterol; 2020 Oct; 55(10):944-957. PubMed ID: 32748173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and emerging immunotherapeutic approaches for biliary tract cancers.
    Yuan ZG; Zeng TM; Tao CJ
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The state of therapy modalities in clinic for biliary tract cancer.
    Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
    Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Treatment Options for Advanced Biliary Tract Cancer.
    Mizrahi JD; Shroff RT
    Curr Treat Options Oncol; 2020 Jun; 21(8):63. PubMed ID: 32602010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translating cancer genomics for precision oncology in biliary tract cancers.
    Haber PK; Sia D
    Discov Med; 2019; 28(155):255-265. PubMed ID: 32053766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of novel biologics in biliary cancers.
    Jordan E; Braghiroli MF; Lowery MA
    Minerva Gastroenterol Dietol; 2016 Dec; 62(4):325-339. PubMed ID: 27576672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.